Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · IEX Real-Time Price · USD
0.701
-0.010 (-1.41%)
Jul 22, 2024, 10:07 AM EDT - Market open
Protagenic Therapeutics Employees
As of December 31, 2023, Protagenic Therapeutics had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees increased by 2 or 200.00% compared to the previous year.
Employees
3
Change
2
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$2,002,232
Market Cap
3.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 2 | 200.00% |
| Dec 31, 2015 | 1 | 0 | - |
| Dec 31, 2014 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aditxt | 47 |
| TC Biopharm (Holdings) | 41 |
| Healthcare Triangle | 31 |
| INVO Bioscience | 30 |
| Petros Pharmaceuticals | 21 |
| Ensysce Biosciences | 7 |
| ZyVersa Therapeutics | 7 |
| Alzamend Neuro | 7 |
PTIX News
- 2 months ago - Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - Accesswire
- 3 months ago - Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit - Accesswire
- 3 months ago - Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Accesswire
- 4 months ago - Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders - Accesswire
- 4 months ago - Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call - Accesswire
- 4 months ago - Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - Accesswire
- 5 months ago - Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders - Accesswire
- 10 months ago - Protagenic Therapeutics Announces Date of Annual Shareholder Meeting - Accesswire